GAITHERSBURG, Md., Feb. 20, 2019 (GLOBE NEWSWIRE) -- OpGen, Inc. (NASDAQ: OPGN) announced today that the Company will report its fourth quarter and fiscal year 2018 financial results after the close of the U.S. financial markets on Tuesday, February 26, 2019. OpGen’s management team will host a live conference call and audio webcast at 4:30 p.m. Eastern time to discuss the Company’s financial results and business progress.
U.S. Dial-In Number: (888) 883-4599
International Dial-In Number: (484) 653-6821
Conference ID: 7268038
Replay Dial-in Information
U.S. Dial-In Number: (855) 859-2056
International Dial-In Number: (404) 537-3406
Conference ID: 7268038
Following the conclusion of the conference call, a replay will be available through March 4, 2019. The live, listen-only webcast of the conference call may also be accessed by visiting the investors section of the Company’s website at www.ir.opgen.com. A replay of the webcast will be available after the conclusion of the call and will be archived on the Company’s website for 90 days.
OpGen, Inc. is harnessing the power of informatics and genomic analysis to provide complete solutions for patient, hospital, and network-wide infection treatment and prevention. The Acuitas Lighthouse® Software (RUO) is the first cloud-based software to predict antibiotic resistance, track antimicrobial resistance, and determine bacterial strain relatedness in healthcare settings using bacterial genetic data. The Acuitas® AMR Gene Panel (RUO) is the most comprehensive, rapid PCR test for detecting five pathogens and 47 resistance genes which cover nine antibiotic classes. OpGen’s solutions will provide the power to prescribe empiric therapy with precision. For more information, please visit www.opgen.com.
OpGen, Acuitas, and Acuitas Lighthouse are registered trademarks of OpGen, Inc.
The Acuitas AMR Gene Panel u5.47 (RUO) and the Acuitas Lighthouse Software (RUO) are intended for Research Use Only and are not for use in diagnostic procedures. The Acuitas Lighthouse Software is not distributed commercially for antibiotic resistance prediction and is not for use in diagnostic procedures.
Vice President, Marketing
LHA Investor Relations
Kim Sutton Golodetz
FischTank Marketing and PR
Source: OpGen, Inc.